APLM (Apollomics) Debt-to-Asset : 0.10 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APLM Apollomics Inc APLM
29 GF Score
Price $17.25
! 4 Warning Signs
View Full Analysis

What is Apollomics Debt-to-Asset?

Apollomics APLM -0.61% 29 Debt-to-Asset is 0.10 as of Dec. 2025. GuruFocus rates APLM with a GF Score™ of 29/100. The stock has 4 warning signs investors should review.

Apollomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.21 Mil. Apollomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.43 Mil. Apollomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $6.71 Mil. Apollomics's debt to asset for the quarter that ended in Dec. 2025 was 0.10.

Apollomics  (NAS:APLM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Apollomics Debt-to-Asset Related Terms

Apollomics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Apollomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Debt-to-Asset Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.01 0.01 0.08 0.07 0.10

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.08 0.14 0.07 0.07 0.10

APLM vs RNXT, ELOX, HYPD: Debt-to-Asset Comparison

For the Biotechnology subindustry, Apollomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Apollomics's Debt-to-Asset falls into.


APLM
29GF Score
Apollomics Inc APLM
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Apollomics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.209 + 0.434) / 6.714
=0.10

Apollomics's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.209 + 0.434) / 6.714
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.10 mean?
Apollomics (APLM) has a Debt-to-Asset of 0.10 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Apollomics and its competitors.
Is Apollomics' Debt-to-Asset too high?
Apollomics' current Debt-to-Asset is 0.10. Overall, Apollomics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Debt-to-Asset compare to RNXT and ELOX?
Apollomics' Debt-to-Asset of 0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Apollomics and its competitors. Apollomics's current Debt-to-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLM) has a current Debt-to-Asset of 0.10. The current Debt-to-Asset is 0.10. Apollomics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Apollomics (APLM), the current Debt-to-Asset is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLMW:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
29GF Score

Get the complete analysis for APLM

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.25
Price